Aim: To evaluate the pharmacokinetics and bioavailability of two formulations of intranasal hydromorphone hydrochloride in adult postoperative patients. Method: In an open-label, randomised, crossover study a convenience sample of adult postoperative patients received intravenous hydromorphone 1 mg and intranasal hydromorphone 2 mg (with and without chitosan). Results: Pharmacokinetic data sets from 19 patients showed intranasal hydromorphone produced detectable serum levels within 2 minutes of administration, with mean bioavailability of 49.5% (without chitosan) and 67.5% (with chitosan). Mean peak serum concentrations were 0.92 ng/mL (without chitosan) and 1.16 ng/mL (with chitosan). Summed pain intensity differences suggest that intravenous hydromorphone produced a better clinical response. Conclusion: The bioavailability of intranasal hydromorphone is approximately 0.6 of intravenous hydromorphone. Adding chitosan to the intranasal solution did not significantly increase the bioavailability of hydromorphone.
|Journal||Journal of Pharmacy Practice and Research|
|Publication status||Published - 2008|